ArticleOncotarget2015
Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Damage-Associated Molecular Patterns in Mesothelioma: Drivers of Inflammation and Therapeutic Targets.International journal of molecular sciences · 2026Review
- Sequestration of ribosomal subunits as inactive 80S by targeting eIF6 limits mitotic exit and cancer progression.Nucleic acids research · 2025Article
- eIF6 Promotes Gastric Cancer Proliferation and Invasion by Regulating Cell Cycle.Digestive diseases and sciences · 2024Article
- Article
- Small and Large Extracellular Vesicles Derived from Pleural Mesothelioma Cell Lines Offer Biomarker Potential.Cancers · 2023Article
- Dynamic states of eIF6 and SDS variants modulate interactions with uL14 of the 60S ribosomal subunit.Nucleic acids research · 2023Article
- eIF6 is potential diagnostic and prognostic biomarker that associated withJournal of translational medicine · 2022Article
- Eukaryotic initiation factor 6 regulates mechanical responses in endothelial cells.The Journal of cell biology · 2022Article
- eIF6 as a Promising Diagnostic and Prognostic Biomarker for Poorer Survival of Cutaneous Melanoma.Frontiers in oncology · 2022Article
- Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway.Cell communication and signaling : CCS · 2021Article
- The pathogenesis of mesothelioma is driven by a dysregulated translatome.Nature communications · 2021Article
- eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway.Journal of translational medicine · 2021Article
- BCCIP is required for nucleolar recruitment of eIF6 and 12S pre-rRNA production during 60S ribosome biogenesis.Nucleic acids research · 2020Article
- Regulation of eukaryotic translation initiation factor 6 dynamics through multisite phosphorylation by GSK3.The Journal of biological chemistry · 2020Article
- Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression.International journal of cancer · 2020Article
- Article
- Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer.Journal of cancer research and clinical oncology · 2019Article
- Overexpression ofDisease markers · 2019Article
- RACK1 Specifically Regulates Translation through Its Binding to Ribosomes.Molecular and cellular biology · 2018Article
- A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma.Cancer research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
eIF6 is an antiassociation factor that regulates the availability of active 80S. Its activation is driven by the RACK1/PKCβ axis, in a mTORc1 independent manner. We previously described that eIF6 haploinsufficiency causes a striking survival in the Eμ-Myc mouse lymphoma model, with lifespans extended up to 18 months. Here we screen for eIF6 expression in human cancers. We show that Malignant Pleural Mesothelioma tumors (MPM) and a MPM cell line (REN cells) contain high levels of hyperphosphorylated eIF6. Enzastaurin is a PKC beta inhibitor used in clinical trials. We prove that Enzastaurin treatment decreases eIF6 phosphorylation rate, but not eIF6 protein stability. The growth of REN, in vivo, and metastasis are reduced by either Enzastaurin treatment or eIF6 shRNA. Molecular analysis reveals that eIF6 manipulation affects the metabolic status of malignant mesothelioma cells. Less glycolysis and less ATP content are evident in REN cells depleted for eIF6 or treated with Enzastaurin (Anti-Warburg effect). We propose that eIF6 is necessary for malignant mesothelioma growth, in vivo, and can be targeted by kinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.